{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-112674","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2025-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.750826+00:00","generated_at":"2026-05-17T08:39:50.370094+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"enGene achieves target enrollment of 100 patients in Phase 2 LEGEND trial for detalimogene in BCG-unresponsive NMIBC","bullets":["Target enrollment of 100 patients reached in Cohort 1 of Phase 2 LEGEND trial.","Trial evaluates detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC with CIS ± papillary disease.","Corporate presentation updated September 3, 2025; news release issued same day."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-112674","json":"https://secwatch.observer/filing/0000950170-25-112674.json","markdown":"https://secwatch.observer/filing/0000950170-25-112674.md","text":"https://secwatch.observer/filing/0000950170-25-112674.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000095017025112674/0000950170-25-112674-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000095017025112674/engn-20250903.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:39:50.370094+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}